Henrik Daub

Henrik Daub's work experience starts with their role as CSO at NEOsphere Biotechnologies GmbH, which began in June 2022. Before that, they worked as a Professor at Technische Universität München from April 2017, and their employment there is ongoing. From April 2012 to March 2022, they held the position of Senior Vice President, Science & Technology at Evotec. Prior to that, from February 2011 to March 2012, they were the Vice President, Science & Technology at the same company. Before joining Evotec, Henrik Daub served as CTO at KINAXO Biotechnologies from July 2010 to January 2011. From July 2005 to June 2010, they worked as a Group Leader in the Department of Molecular Biology at the Max Planck Institute for Biochemistry. In December 2005, they also founded KINAXO Biotechnologies. Prior to that, from July 2000 to June 2005, Henrik Daub worked as the Group Leader for Proteomics & Chemical Genetics at Axxima Pharmaceuticals AG. Henrik'scareer began at the MRC Laboratory for Molecular Cell Biology (LMCB), UCL, where they were a Postdoc from July 1998 to June 2000.

Henrik Daub began their education in 1989 by enrolling at the University of Regensburg. Henrik pursued a Diploma in Biochemistry, completing their studies in 1994. Afterward, they continued their academic journey at the Max Planck Institute of Biochemistry, Department of Molecular Biology. Henri Daub conducted research in Cancer and earned their PhD in Cancer Research (Dr. rer. nat.) in 1998. Finally, from 2005 to 2010, they attended the Technical University of Munich, where they achieved a Habilitation, Venia Legendi in Biochemistry. The specific field of study for each degree is not provided.